358 related articles for article (PubMed ID: 25311884)
1. Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures.
Rosenthaler S; Pöhn B; Kolmanz C; Huu CN; Krewenka C; Huber A; Kranner B; Rausch WD; Moldzio R
Neurotoxicol Teratol; 2014; 46():49-56. PubMed ID: 25311884
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
4. Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.
Moldzio R; Pacher T; Krewenka C; Kranner B; Novak J; Duvigneau JC; Rausch WD
Phytomedicine; 2012 Jun; 19(8-9):819-24. PubMed ID: 22571976
[TBL] [Abstract][Full Text] [Related]
5. The structurally diverse phytocannabinoids cannabichromene, cannabigerol and cannabinol significantly inhibit amyloid β-evoked neurotoxicity and changes in cell morphology in PC12 cells.
Marsh DT; Sugiyama A; Imai Y; Kato R; Smid SD
Basic Clin Pharmacol Toxicol; 2024 Mar; 134(3):293-309. PubMed ID: 37697481
[TBL] [Abstract][Full Text] [Related]
6. Molecular Targets of the Phytocannabinoids: A Complex Picture.
Morales P; Hurst DP; Reggio PH
Prog Chem Org Nat Prod; 2017; 103():103-131. PubMed ID: 28120232
[TBL] [Abstract][Full Text] [Related]
7. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.
De Petrocellis L; Vellani V; Schiano-Moriello A; Marini P; Magherini PC; Orlando P; Di Marzo V
J Pharmacol Exp Ther; 2008 Jun; 325(3):1007-15. PubMed ID: 18354058
[TBL] [Abstract][Full Text] [Related]
8. Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol.
Pagano E; Montanaro V; Di Girolamo A; Pistone A; Altieri V; Zjawiony JK; Izzo AA; Capasso R
Nat Prod Commun; 2015 Jun; 10(6):1009-12. PubMed ID: 26197538
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Rock EM; Sticht MA; Duncan M; Stott C; Parker LA
Br J Pharmacol; 2013 Oct; 170(3):671-8. PubMed ID: 23902479
[TBL] [Abstract][Full Text] [Related]
10. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
Oláh A; Markovics A; Szabó-Papp J; Szabó PT; Stott C; Zouboulis CC; Bíró T
Exp Dermatol; 2016 Sep; 25(9):701-7. PubMed ID: 27094344
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant function of phytocannabinoids: Molecular basis of their stability and cytoprotective properties under UV-irradiation.
Vacek J; Vostalova J; Papouskova B; Skarupova D; Kos M; Kabelac M; Storch J
Free Radic Biol Med; 2021 Feb; 164():258-270. PubMed ID: 33453360
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
13. An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.
Straiker A; Wilson S; Corey W; Dvorakova M; Bosquez T; Tracey J; Wilkowski C; Ho K; Wager-Miller J; Mackie K
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500785
[TBL] [Abstract][Full Text] [Related]
14. Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.
Blebea NM; Pricopie AI; Vlad RA; Hancu G
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673788
[TBL] [Abstract][Full Text] [Related]
15. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
Hill TD; Cascio MG; Romano B; Duncan M; Pertwee RG; Williams CM; Whalley BJ; Hill AJ
Br J Pharmacol; 2013 Oct; 170(3):679-92. PubMed ID: 23902406
[TBL] [Abstract][Full Text] [Related]
16. Cannabichromene is a cannabinoid CB
Udoh M; Santiago M; Devenish S; McGregor IS; Connor M
Br J Pharmacol; 2019 Dec; 176(23):4537-4547. PubMed ID: 31368508
[TBL] [Abstract][Full Text] [Related]
17. Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood-Brain Barrier Under Ischemic Conditions.
Stone NL; England TJ; O'Sullivan SE
Cannabis Cannabinoid Res; 2021 Aug; 6(4):315-326. PubMed ID: 33998890
[No Abstract] [Full Text] [Related]
18. Molecular Pharmacology of Phytocannabinoids.
Turner SE; Williams CM; Iversen L; Whalley BJ
Prog Chem Org Nat Prod; 2017; 103():61-101. PubMed ID: 28120231
[TBL] [Abstract][Full Text] [Related]
19. Novel cannabinol probes for CB1 and CB2 cannabinoid receptors.
Mahadevan A; Siegel C; Martin BR; Abood ME; Beletskaya I; Razdan RK
J Med Chem; 2000 Oct; 43(20):3778-85. PubMed ID: 11020293
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
